Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG) at Chughtai Lab

Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG) at Chughtai Lab

The Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG) molecular assay at Chughtai Lab is a premier, highly sensitive diagnostic test designed to detect the presence of two of the most prevalent bacterial sexually transmitted infections (STIs) globally. Chlamydia trachomatis and Neisseria gonorrhoeae are major causes of reproductive tract morbidity, often presenting as asymptomatic infections that, if left untreated, can lead to severe, irreversible clinical complications. Chughtai Lab utilizes state-of-the-art Nucleic Acid Amplification Testing (NAAT) technology, specifically real-time Polymerase Chain Reaction (PCR), to identify the specific DNA or RNA sequences of these pathogens. This advanced molecular approach offers unparalleled diagnostic sensitivity and specificity compared to traditional culture or antigen detection methods, ensuring that patients receive the most accurate results possible.

The anatomical structures evaluated during this investigation depend on the specimen type collected. For female patients, the test typically analyzes endocervical, vaginal, or urethral specimens, while for male patients, urethral swabs or first-catch urine samples are standard. Additionally, extragenital specimens, such as pharyngeal or rectal swabs, can be processed to evaluate infections acquired through oral or anal exposure. The clinical importance of the CTNG test cannot be overstated; early and accurate detection is vital for preventing the upward spread of bacteria into the upper reproductive tract. In women, untreated infections can cause Pelvic Inflammatory Disease (PID), fallopian tube scarring, ectopic pregnancy, and tubal factor infertility. In men, these pathogens can cause acute urethritis, epididymitis, and potential fertility issues. By providing rapid, precise, and highly confidential testing, Chughtai Lab plays a critical role in sexual health management, infectious disease control, and the prevention of long-term reproductive complications across Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

Appropriate patient preparation is essential to guarantee the clinical integrity of the specimen and prevent false-negative or invalid test results. Patients undergoing the Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG) test at Chughtai Lab must adhere to the following preparation guidelines:

• Urine Specimen Collection: If a urine sample is being submitted, the patient must collect the “first-catch” urine. This is the very first part of the urine stream (approximately 20 to 30 mL) and not a mid-stream sample. The patient must not have urinated for at least one to two hours prior to specimen collection to ensure that the bacterial DNA is concentrated in the urethra.
• Vaginal and Endocervical Swabs: Female patients should avoid vaginal douching, using spermicides, contraceptive jellies, vaginal creams, or therapeutic suppositories for at least 24 to 48 hours before the test, as these substances can interfere with the PCR amplification process.
• Menstruation Considerations: While PCR testing can still detect bacterial DNA in the presence of minor blood, it is highly recommended to schedule the test outside of active menstrual periods to prevent sample dilution and optimize collection comfort.
• Antibiotic Therapy: Patients must inform the laboratory staff if they are currently taking or have recently completed a course of antibiotics. Antibiotic therapy can suppress the bacterial load, leading to false-negative results. For a test-of-cure, it is clinically recommended to wait at least 14 to 21 days after completing antibiotic treatment before repeating the CTNG test.
• Sexual Activity: It is advisable to avoid sexual intercourse for 24 hours prior to swab collection to prevent sample contamination or dilution.

During the Procedure

The collection process for the CTNG test is streamlined, hygienic, and designed to maximize patient comfort and privacy. Depending on the clinical indication and patient gender, one of the following collection methods will be utilized at Chughtai Lab:

• First-Catch Urine Collection (Male and Female): The patient is provided with a sterile, preservative-free collection cup. After washing their hands, the patient collects the initial 20 to 30 mL of their urine stream directly into the cup. The remaining urine is discarded in the toilet. The cup is then securely capped and handed to the laboratory technician.
• Clinician-Collected Endocervical Swab (Female): During a pelvic examination, a clinician inserts a sterile speculum to visualize the cervix. A clearing swab is first used to remove excess mucus from the ectocervix. A sterile diagnostic swab is then inserted into the endocervical canal, rotated gently for 10 to 30 seconds to collect epithelial cells (where Chlamydia intracellularly resides), and carefully withdrawn. The swab is immediately placed into the transport medium tube.
• Self-Collected or Clinician-Collected Vaginal Swab (Female): A sterile swab is inserted approximately 2 inches into the vaginal vault, rotated gently against the vaginal walls for 10 to 15 seconds, and placed directly into the transport tube. This method is highly tolerated and clinically validated as highly sensitive for NAAT.
• Urethral Swab (Male): While less common due to the high accuracy of urine PCR, a thin, sterile swab may be inserted gently into the male urethra (about 2 to 4 cm), rotated, and placed in transport media.
• Extragenital Swabs (Pharyngeal and Rectal): For suspected extragenital infections, a sterile swab is rubbed against the posterior pharynx and tonsillar pillars (pharyngeal) or inserted approximately 2 to 3 cm into the anal canal and rotated (rectal).

All specimens are labeled immediately with unique patient identifiers and transported under temperature-controlled conditions to the molecular diagnostics department of Chughtai Lab for PCR processing.

When is a Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG) Performed?

Screening for Sexually Transmitted Infections (STIs)

Routine screening is highly recommended for sexually active individuals, particularly those under the age of 25, as both Chlamydia and Gonorrhea frequently present without any noticeable symptoms. Annual screening is also indicated for individuals with new or multiple sexual partners, inconsistent condom use, or a history of prior STIs. Because asymptomatic individuals can unknowingly transmit the infections, routine screening is a cornerstone of public health and preventive medicine.

Evaluation of Genitourinary Symptoms

Physicians request the CTNG test when a patient presents with classic symptoms of genitourinary inflammation. In women, these symptoms include abnormal vaginal discharge (often mucopurulent), dysuria (painful urination), pelvic pain, intermenstrual bleeding, or post-coital bleeding. In men, symptoms include urethral discharge (ranging from clear to thick and purulent), dysuria, urethral itching, or testicular pain and swelling. The test allows clinicians to differentiate between these two common pathogens and prescribe targeted antibiotic therapy.

Prevention of Pelvic Inflammatory Disease (PID)

Pelvic Inflammatory Disease is a severe complication that occurs when *C. trachomatis* or *N. gonorrhoeae* ascends from the cervix to the endometrium, fallopian tubes, and ovaries. Patients presenting with lower abdominal pain, adnexal tenderness, and fever are urgently tested for CTNG. Identifying the causative pathogen assists the physician in selecting the appropriate intravenous or oral antibiotic regimen to prevent tubal scarring, which is a primary cause of ectopic pregnancies and permanent infertility.

Prenatal Screening and Maternal Health

Pregnant women are routinely screened for CTNG during their first prenatal visit, and often again in the third trimester if they are at high risk. Untreated maternal chlamydial or gonococcal infections can lead to premature rupture of membranes, preterm labor, and low birth weight. Furthermore, these infections can be transmitted to the neonate during vaginal delivery, resulting in ophthalmia neonatorum (severe neonatal conjunctivitis that can cause blindness) or neonatal chlamydial pneumonia.

Partner Notification and Post-Treatment Follow-up

When an individual tests positive for Chlamydia or Gonorrhea, their sexual partners must be notified, evaluated, and treated empirically. The CTNG test is performed on partners to confirm infection status and monitor for co-infections. Additionally, a follow-up test (test-of-cure) is performed in specific clinical scenarios, such as in pregnant patients three to four weeks post-treatment, or in cases where symptoms persist, to ensure successful eradication of the bacteria.

What Does a Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG) Detect?

The CTNG molecular assay is designed to detect specific nucleic acid sequences (DNA or RNA) of the target pathogens. The test can identify and differentiate the following clinical findings:

• Active infection with Chlamydia trachomatis in the endocervical canal.
• Active infection with Chlamydia trachomatis in the male or female urethra.
• Active infection with Neisseria gonorrhoeae in the endocervical canal.
• Active infection with Neisseria gonorrhoeae in the male or female urethra.
• Co-infection with both Chlamydia trachomatis and Neisseria gonorrhoeae simultaneously.
• Extragenital Chlamydia trachomatis infection of the pharyngeal mucosa.
• Extragenital Neisseria gonorrhoeae infection of the pharyngeal mucosa.
• Extragenital Chlamydia trachomatis infection of the rectal mucosa.
• Extragenital Neisseria gonorrhoeae infection of the rectal mucosa.
• Absence of detectable Chlamydia trachomatis nucleic acids (Negative result).
• Absence of detectable Neisseria gonorrhoeae nucleic acids (Negative result).
• Persistent infection due to antibiotic treatment failure or resistance (particularly relevant in Neisseria gonorrhoeae).
• Reinfection from an untreated or new sexual partner post-treatment.
• The underlying bacterial etiology of acute pelvic inflammatory disease (PID).
• The underlying bacterial cause of mucopurulent cervicitis in female patients.
• The underlying bacterial cause of acute urethritis in male patients.
• The underlying bacterial cause of acute epididymitis in young men.
• The potential risk source for neonatal ophthalmia neonatorum in pregnant patients.
• The potential risk source for neonatal chlamydial pneumonia.
• The underlying cause of infectious proctitis in patients presenting with rectal pain, tenesmus, or discharge.
• The underlying cause of persistent, unexplained pharyngitis in patients with exposure history.
• An increased biological susceptibility to acquiring or transmitting Human Immunodeficiency Virus (HIV).
• The necessity for immediate, targeted antibiotic therapy for the patient and their partner(s).
• The clinical resolution of infection when used as a post-treatment test-of-cure.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is widely recognized for its efficiency, accuracy, and advanced laboratory infrastructure. The turnaround time (TAT) for the Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG) PCR test is typically within 24 to 48 hours from the time of specimen receipt at the molecular diagnostics laboratory. Because molecular testing requires precise thermal cycling and DNA extraction protocols, this timeline ensures rigorous quality control and verification of results by consultant microbiologists and molecular pathologists.

Patients can access their diagnostic reports conveniently and securely. Chughtai Lab provides multiple digital avenues for report retrieval, including their official online patient portal, the Chughtai Lab mobile application, and direct delivery via WhatsApp or email. Patients also receive an automated SMS notification containing a direct download link as soon as the report is finalized. For those who prefer physical copies, reports can be collected from any Chughtai Lab collection center nationwide.

Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Chlamydia trachomatis DNA/RNA	Not Detected (Negative)	Detected (Positive) – Indicates active chlamydial infection
Neisseria gonorrhoeae DNA/RNA	Not Detected (Negative)	Detected (Positive) – Indicates active gonococcal infection
Endocervical / Vaginal Mucosa	No pathogen genetic material identified	Presence of CT and/or NG DNA; clinically correlates with cervicitis or vaginitis
Urethral Epithelium (Male/Female)	No pathogen genetic material identified	Presence of CT and/or NG DNA; clinically correlates with acute urethritis
Pharyngeal Mucosa (Extragenital)	No pathogen genetic material identified	Presence of CT and/or NG DNA; indicates pharyngeal colonization/infection
Rectal Mucosa (Extragenital)	No pathogen genetic material identified	Presence of CT and/or NG DNA; clinically correlates with proctitis
Internal Control (PCR Validation)	Valid / Passed	Invalid – Indicates presence of PCR inhibitors or inadequate cellular sample

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG)?

• Experienced healthcare professionals: Your tests are processed and interpreted by highly qualified molecular pathologists and microbiologists.
• Patient-focused care: Chughtai Lab prioritizes patient comfort, absolute confidentiality, and professional counseling throughout the testing process.
• Quality diagnostic services: Utilizing state-of-the-art real-time PCR technology ensures the highest sensitivity and specificity for STI detection.
• Professional reporting: Clear, comprehensive, and easy-to-understand reports that facilitate quick clinical decision-making for your physician.
• Modern diagnostic approach: Continuous integration of the latest molecular diagnostic assays and international laboratory standards.
• Comfortable environment: Clean, hygienic, and private sample collection spaces designed to make patients feel at ease.
• Convenient location: A vast network of collection centers across Pakistan, making high-quality diagnostics accessible to everyone.
• Commitment to accurate diagnosis: Strict internal and external quality control protocols to eliminate the risk of false-positive or false-negative results.